Presenting on Emerging Growth Conference 88 Day 1 on December 10; Register to live stream
Goldman Small Cap Research Publishes New Research Report on Regen BioPharma, Inc.
Goldman Small Cap Research Publishes New Research Report on Regen BioPharma, Inc.
Regen BioPharma, Inc. Expands Vision for Phase 1 Clinical Trial of HemaXellerate™
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on September 25, 2024, At 4 pm Eastern Time
Regen BioPharma, Inc. to Discuss Plans to Move Forward with HemaXellerate into Clinical Phase 1 at the Emerging Growth Conference on April 4, 2024
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on January 10, 2024
Regen BioPharma, Inc. CEO Outlines Future Steps in CAR T Program
Regen BioPharma, Inc. to Discuss Confirmation Study Results on Its DuraCar Program at the Emerging Growth Conference on November 1, 2023
Regen BioPharma, Inc. Receives Second Phase Confirmatory Data on its Duracar CAR-T Cell Therapy Program
Goldman Small Cap Research Publishes New Research Report on Regen BioPharma, Inc.
Studies On Regen BioPharma, Inc.'s DURACAR Indicate Potential Suppression Of Autoimmunity, Company Retains Contract Research Organization To Conduct Additional Confirmatory Studies
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on February 8, 2023
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on January 25, 2023
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on November 30, 2022